InterCure Ltd. (INCR)
NASDAQ: INCR · Real-Time Price · USD
1.735
-0.005 (-0.29%)
Nov 4, 2024, 3:59 PM EST - Market closed
InterCure Employees
InterCure had 270 employees as of December 31, 2023. The number of employees decreased by 100 or -27.03% compared to the previous year.
Employees
270
Change (1Y)
-100
Growth (1Y)
-27.03%
Revenue / Employee
$268,226
Profits / Employee
-$64,553
Market Cap
82.45M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 270 | -100 | -27.03% |
Dec 31, 2022 | 370 | 20 | 5.71% |
Dec 31, 2021 | 350 | 275 | 366.67% |
Dec 31, 2020 | 75 | 0 | - |
Dec 31, 2019 | 75 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Coherus BioSciences | 306 |
PMV Pharmaceuticals | 63 |
Aerovate Therapeutics | 51 |
Ikena Oncology | 43 |
Vistagen Therapeutics | 40 |
Ovid Therapeutics | 40 |
Renovaro | 25 |
MediciNova | 13 |
INCR News
- 7 weeks ago - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
- 2 months ago - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewsWire
- 2 months ago - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
- 4 months ago - InterCure: A Cannabis Industry Leader Still Flying Under The Radar - Seeking Alpha
- 5 months ago - InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference - Business Wire
- 6 months ago - InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
- 7 months ago - InterCure: Bargain Israel Cannabis Play - Seeking Alpha
- 7 months ago - InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire